Ficerafusp alfa plus nivolumab for head and neck cancer that returned after treatment
Tests ficerafusp alfa with nivolumab versus nivolumab alone in head and neck cancer.
Key facts
- Who runs it
- Groupe Oncologie Radiotherapie Tete Cou
- Where
- Amiens Cedex 1, Angers, Avignon, Brest, Caen Cedex 5, Créteil, Grenoble Cedex 9, Guilherand-Granges, Le Mans Cedex 2, Lille, Lorient, Lyon, Marseille, Nice Cedex 2, Nimes Cedex 9, Paris Cedex 20, Reims Cedex, Rouen Cedex, Saint Nazaire Cedex, Saint-Herblain Cedex, Strasbourg, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, and Villejuif, FranceSee the 24 sites
- Trial code
- Registry title
- Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 121 people, planned
- Started
- 3 Jul 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 12 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with squamous cell cancer of the head and neck whose cancer came back or grew within 6 months after platinum-based treatment given for locally advanced disease.
- Age
- Older than 18 years and up to 75 years.
- Sex
- All sexes can join.
- Disease stage
- Squamous cell carcinoma of the oral cavity, larynx, hypopharynx or oropharynx. The cancer progressed locally, in nearby areas or in the body within 6 months after the last platinum dose in multimodal treatment for locally advanced disease. Surgery to remove it again must not be possible. A tumor that can be measured on CT or MRI is needed. ECOG performance status 0 or 1.
- Earlier treatment
- Must have had platinum as part of multimodal treatment for locally advanced disease. Must not have had systemic treatment for metastatic or recurrent disease, anti-EGFR antibody, anti-TGF-β therapy, or anti-PD1 or anti-PD-L1 therapy.
- Biomarker or test result
- For oropharynx cancer, the p16 test (HPV status) must be negative.
Main reasons for not taking part
- Cancer starting in the nasopharynx, paranasal sinuses, nasal cavity, salivary gland, thyroid, parathyroid or skin, unknown primary, or non-squamous types
- Past or current pneumonitis or interstitial lung disease (non-infectious)
- Active brain or spinal cord metastases, or carcinomatous meningitis
- Another cancer treated in the last 2 years, with a few listed exceptions
- Heart attack, stroke, severe angina or heart failure (NYHA Class III/IV) in the last 6 months
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patient is >18 years, ≤75 years of age on the day the ICF is signed
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Histologically or cytologically confirmed squamous cell carcinoma of head and neck (HNSCC). Eligible primary tumor locations are oral cavity, larynx hypopharynx, or oropharynx (OPSCC)
- Local, regional or metastatic progression within 6 months after the last dose of platinum in a multimodal strategy for locally advanced stage, not amenable to salvage surgery in case of local or regional progression. Specification regarding inclusion criterion no. 05 : The pProgression is not assessed as per RECIST. and Any of the following that will be considered as a progression any of the following items : o A positive biopsy 3 months after the end of radiotherapy given with curative intent o Appearance of any new lesion (exe.g.: metastases or lymph nodes) o Any increase in tumor size o Any persisting tumor (confirmed with a biopsy) not amenable to salvage surgery
- For OPSCC patients, a pathological report determination of human papillomavirus (HPV) status by p16 expression must be p16 negative
- Measurable tumor lesion(s) assessed by H&N-computed tomography scan (CT-scan) or magnetic resonance imaging (MRI), based on RECIST v 1.1 (see Appendix 3). Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated
Who cannot take part
- Active central nervous system (CNS) metastases or carcinomatous meningitis. Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded. Patients with a history of treated central nervous system metastases (by surgery or radiation therapy) may be eligible if central nervous system metastases have been stable for at least 4 weeks, i.e., without evidence of progression by repeat imaging and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
- Subjects having received prior systemic treatment for metastatic or recurrent disease
- Subjects having received prior treatment with anti-TGF-β therapy
- Subjects having received prior therapy with anti-PD1, anti-PD-L1 (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
- Patient who participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy or at least 4 weeks if half live of the agent received is not known before enrollment
- Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to registration/randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer defined as follows: Stage T1 up to T2a with a Gleason score ≤6 and prostatic specific antigen <10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to registration/randomization. Other exceptions may be considered with the Sponsor’s consultation. The time requirement for no malignancy for 2 years does not apply to the cancer for which a patient is enrolled in the study
- Any of the following <6 months before starting study treatment: ST-elevation myocardial infarction, severe/unstable angina, uncontrolled cardiac ventricular arrythmia, coronary/peripheral artery bypass graft or stent, cerebrovascular accident/stroke less than 6 months prior to enrollment or NYHA Class III/IV congestive heart failure. Subjects with deep vein thrombosis who are hemodynamically stable can enroll if they are on a stable dose of anticoagulants for at least 3 months
- Serious systemic infection (bacterial, viral, or fungal) within 4 weeks before first dose of study treatment, or active systemic infection requiring either hospitalization or parenteral anti-infective therapy within 2 weeks before first dose of study treatment
- History of (non-infectious) pneumonitis/ interstitial lung disease or has current pneumonitis/ Interstitial lung disease
- History of uncontrolled seizures, CNS disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance
- Subjects having received prior treatment with anti-EGFR antibody
- Primary tumor of nasopharyngeal, paranasal sinuses, nasal cavity or salivary gland, thyroid or parathyroid gland pathologies, skin, squamous cell carcinoma of unknown primary or non-squamous histologies (e.g., mucosal melanoma)
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceTaking people
- Institut de Cancerologie de L'OuestAngers, FranceTaking people
- Institut Sainte-CatherineAvignon, FranceTaking people
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceTaking people
- Centre Francois BaclesseCaen Cedex 5, FranceTaking people
- Centre Hospitalier Intercommunal CréteilCréteil, FranceTaking people
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceTaking people
- Hopital Privé Drome-ArdecheGuilherand-Granges, FranceTaking people
- Clinique Victor HugoLe Mans Cedex 2, FranceTaking people
- Centre Oscar LambretLille, FranceTaking people
- Groupe Hospitalier Bretagne SudLorient, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
- Centre Antoine LacassagneNice Cedex 2, FranceTaking people
- Centre Hospitalier Universitaire De NimesNimes Cedex 9, FranceTaking people
- Hopital TenonParis Cedex 20, FranceTaking people
- Centre Hospitalier Universitaire ReimsReims Cedex, FranceTaking people
- Centre Henri BecquerelRouen Cedex, FranceTaking people
- Centre Hospitalier Saint NazaireSaint Nazaire Cedex, FranceTaking people
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranceTaking people
- Institut de Cancérologie Strasbourg EuropeStrasbourg, FranceTaking people
- Oncopole Claudius RegaudToulouse Cedex 9, FranceTaking people
- Institut de cancérologie de LorraineVandoeuvre Les Nancy_ Cedex, FranceTaking people
- Institut Gustave RoussyVillejuif, FranceTaking people
About the trial
What the trial wants to find out
The primary objective is to compare the objective response rate (ORR) of patients with platinum refractory HNSCC with progressive disease within the 6 months after multimodal curative treatment treated with ficerafusp alfa (BCA 101) and nivolumab versus nivolumab alone.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)
- Plain-language title
- Ficerafusp alfa plus nivolumab for head and neck cancer that returned after treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 October 2026